Bristol-myers Squibb Company
ROME, July 20, 2011 -
Boosted REYATAZ shows durable
viral suppression in
antiretroviral-experienced
women living with HIV, in a
gender-specific sub-analysis of a large retrospective
cohort study(1)
Bristol-Myers Squibb Company announced results from a long-term,
retrospective, European cohort study, which included 1,294
antiretroviral (ARV)-experienced patients (336 female and 958 male)
from Germany, France and Sweden, that were presented today at the
Sixth International AIDS Society Conference on HIV Pathogenesis,
Treatment and Prevention (IAS 2011).
GLASGOW, Scotland, November 9, 2010 - Results from a European Observational Study, which included 1,294
antiretroviral (ARV)-experienced patients presented today at the Tenth
International Congress on Drug Therapy in HIV Infection (HIV10), demonstrated
a low rate of discontinuation and sustained virologic suppression with
REYATAZ(R) (atazanavir/ritonavir)-based regimens over a follow-up period of
up to five years.(1)
The aim of this study was to investigate the long-term outcomes of
REYATAZ/ritonavir-containing regimens in ARV-experienced patients in a
real-life clinical setting.
VIENNA, July 20, 2010 - Bristol-Myers Squibb Company (NYSE: BMY) and the Bristol-Myers Squibb
Foundation announced at the XVIII International AIDS Conference in Vienna the
community-based projects that it is currently supporting in resource-poor
regions across Africa to help combat the challenge of HIV and tuberculosis
co-infection.
